# reload+after+2024-01-21 19:45:24.611659
address1§New Bund Center
address2§55th Floor 555 West Haiyang Road Pudong District
city§Shanghai
zip§200124
country§China
phone§86 21 6057 8000
website§https://www.i-mabbiopharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jingwu Zhang  Zang M.D., Ph.D.', 'age': 66, 'title': 'Chairman & Founder', 'yearBorn': 1957, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Raj  Kannan', 'age': 59, 'title': 'CEO & Director', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andrew X.  Zhu M.D., Ph.D.', 'age': 63, 'title': 'Member of Scientific Advisory Board, President & Director', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jerry  Wang', 'title': 'Co-Founder & Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard L.  Yeh CLP, Esq., M.B.A.', 'age': 55, 'title': 'Interim CFO, COO & Director', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tianyi  Zhang', 'title': 'Vice President of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Cheng  Li', 'age': 39, 'title': 'Chief Legal Officer', 'yearBorn': 1984, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Gigi Qi  Feng', 'age': 42, 'title': 'Chief Communications Officer', 'yearBorn': 1981, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Weiming  Tang Ph.D.', 'age': 57, 'title': 'Executive VP of Global Business Development & Chief Business Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fernando J.  Salle´s Ph.D.', 'title': 'Senior VP and Head of U.S. & EU Business Development', 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.113
priceToSalesTrailing12Months§-0.6935036
currency§USD
dateShortInterest§1702598400
forwardEps§-1.47
exchange§NGM
quoteType§EQUITY
shortName§I-MAB
longName§I-Mab
firstTradeDateEpochUtc§1579271400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c6b59f81-f79d-304b-8bda-ce05727aace4
gmtOffSetMilliseconds§-18000000
targetHighPrice§101.0
targetLowPrice§15.0
targetMeanPrice§33.33
targetMedianPrice§20.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§4.442
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
